Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab alone versus ranibizumab plus verteporfin photodynamic therapy for retinal angiomatous proliferation
2006-004126-85Phase 2Active
- Sponsor
- Dr. Lluis Arias
- Start
- Mar 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in retinal angiomatous proliferation (RAP) comparing Ranibizumab monotherapy with Ranibizumab plus verteporfin photodynamic therapy (2 arms). Primary endpoints: Mean change in best-corrected visual acuity at 6 months and Mean change in best-corrected visual acuity at 12 months. Started Mar 2010; status: active.
02
Drugs
ranibizumabverteporfin
03
Conditions
retinal angiomatous proliferation (RAP)
Beyond the preview
Go deeper on 2006-004126-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004126-85.